Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Left ventricular hypertrophy (LVH) is a frequent finding in Friedreich's ataxia (FRDA). In previous studies treatment with idebenone, a synthetic analogue of coenzyme Q10, has been associated with a substantial decrease in myocardial hypertrophy, despite great variability in cardiac responsiveness among patients. Here we present the results of a retrospective analysis of a cohort of 35 patients (20 with LVH, 15 without LVH) with confirmed molecular diagnosis of FRDA, treated with idebenone 5 mg/kg/day for up to five years. At the end of the study, we found an increase of interventricular septum and posterior wall thickness in the group without LVH before treatment and no change in the group with LVH before treatment. The neurological picture of the disease significantly deteriorated with time in both groups.

Original publication

DOI

10.1007/s00415-009-5130-6

Type

Journal article

Journal

J Neurol

Publication Date

09/2009

Volume

256

Pages

1434 - 1437

Keywords

Adult, Analysis of Variance, Antioxidants, Cohort Studies, Echocardiography, Female, Follow-Up Studies, Friedreich Ataxia, Heart, Heart Septum, Humans, Hypertrophy, Left Ventricular, Male, Myocardium, Retrospective Studies, Severity of Illness Index, Ubiquinone